Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated December 16, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries. The filing details specific transactions executed under a programme initiated on November 11, 2024, which is part of a broader authorization to repurchase up to DKK 20 billion over a 12-month period starting February 6, 2024.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities and does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels.
- Share Repurchase Programme Limit: Up to DKK 20 billion (12-month period from Feb 6, 2024).
- Specific Programme Limit (Nov 11, 2024): Up to DKK 3,136,206,122.30.
- Total Repurchased (Since Feb 6, 2024): 22,199,078 B shares.
- Total Value Repurchased (Since Feb 6, 2024): DKK 18,370,178,634.
- Average Share Price (Since Feb 6, 2024): DKK 827.52 per B share.
- Treasury Shares Held: 23,343,636 B shares (0.5% of share capital).
- Recent Transaction Volume (Dec 9-13, 2024): 381,000 B shares purchased.
Material Changes
Since the previous announcement on December 9, 2024, Novo Nordisk executed five additional transactions between December 10 and December 13, 2024. These transactions increased the accumulated volume under the specific November 11 programme to 1,995,979 shares with a total value of DKK 1,506,384,757. The average purchase price for these recent transactions ranged between DKK 762.70 and DKK 790.85.
Guidance, Outlook, and Risks
The company expects to continue repurchasing B shares up to the total authorized amount of DKK 20 billion during the 12-month period beginning February 6, 2024. The filing does not provide specific operational guidance, risk factors, or management commentary regarding future earnings or market conditions beyond the execution of the buyback programme.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 20 billion total repurchase authorization (approx. DKK 1.63 billion remaining based on reported figures).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average purchase price of DKK 762.70–790.85.
- Review the full transaction history on novonordisk.com for details on all repurchases since February 6, 2024.
- Check for any updates to the company's treasury share count, currently reported at 0.5% of total share capital.